Canagliflozin Targeting Vascular Inflammation

Launched by OTTAWA HEART INSTITUTE RESEARCH CORPORATION · Jun 16, 2022

Keywords

ClinConnect Summary

The CANTOR SING clinical trial is studying the effects of a medication called canagliflozin on patients with type 2 diabetes who also have coronary artery disease (CAD). Specifically, the researchers want to see how this medication impacts inflammation in the blood vessels after six months of treatment. The trial will involve 16 patients in total, with half receiving the medication and the other half receiving a placebo (a substance with no active drug) to compare the results.

To be eligible for this trial, participants must have stable coronary artery disease, meaning they are at least 60 days post-heart attack, and also have diabetes. Patients who have severe heart issues, active infections, or certain other health conditions will not be able to participate. Those who join the study can expect to be monitored closely over the six months to track changes in their condition. This trial is currently recruiting participants, and all individuals will need to provide informed consent before joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) Stable CAD (over 60 days post-myocardial infarction).
• • 2) Diabetes
• • 3) given informed consent.
• Exclusion Criteria:
• • 1. severe LV dysfunction (EF\<50%);
• • 2. decompensated heart failure;
• • 3. active infection (e.g. pneumonia, active skin infections, and on antibiotics);
• • 4. active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate));
• • 5. pregnancy (all women of child bearing potential will have a negative BHCG test;
• • 6. breastfeeding;
• • 7. Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception.
• • 8. glomerular filtration rate (GFR) \<50 ml/min/1.72m2;
• • 9. Use of p-glycoprotein inhibitor (e.g. cyclosporine, verapamil, or quinidine) or a strong CYP3A4 inhibitor (e.g. ritonavir, clarithromycin, or ketoconazole);
• • 10. Hemoglobin \< 105(women) \<110 (men) g/L; WBC \< 3.0x 10(9)/L, platelet count\< 110x 10(9)/L;
• • 11. Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease or with alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal.
• • 12. unable to give informed consent;